Cargando…
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
Anticalin(®) proteins have been proven as versatile clinical stage biotherapeutics. Due to their small size (∼20 kDa), they harbor a short intrinsic plasma half-life which can be extended, e.g., by fusion with IgG or Fc. However, for antagonism of co-immunostimulatory Tumor Necrosis Factor Receptor...
Autores principales: | Siegemund, Martin, Oak, Prajakta, Hansbauer, Eva-Maria, Allersdorfer, Andrea, Utschick, Karoline, Winter, Alexandra, Grasmüller, Christina, Galler, Gunther, Mayer, Jan-Peter, Weiche, Benjamin, Prassler, Josef, Kontermann, Roland E., Rothe, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573339/ https://www.ncbi.nlm.nih.gov/pubmed/34759826 http://dx.doi.org/10.3389/fphar.2021.759337 |
Ejemplares similares
-
Anticalin(®) Proteins as Therapeutic Agents in Human Diseases
por: Rothe, Christine, et al.
Publicado: (2018) -
The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
por: Peper-Gabriel, Janet K., et al.
Publicado: (2022) -
OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021) -
OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012) -
OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)